James Blanchard

TL;DR: These experiments provide the first direct evidence that transient mucosal infection can induce SIV-specific immunity that remains localized to the gut-associated tissues and protection against colonic mucosal challenge was observed.

TL;DR: The long-acting integrase inhibitor GSK744 protects macaques from three high-dose SHIV challenges at plasma drug concentrations that could be achieved with quarterly injections in humans and was shown to be an effective preexposure prophylaxis (PrEP) agent in a low-dose intrarectal SHIV rhesus macaque challenge model.

TL;DR: Analysis of cellular immune responses revealed slower response rates in virus-specific IFN-gamma production to SIV Gag in the Depo-treated macaques, which may account for the increase viral burden and diversity and the predominance of X4 virus replication in SHIV infected macaques that were administered the progestin-based contraceptive.

TL;DR: Lung gene expression correlates of protective response against tuberculosis, relative to disease, are defined and can potentially be employed to assess the efficacy of candidate antituberculosis vaccines.

TL;DR: A combination MIV-150/zinc acetate Gel and a zinc acetate gel provide significant protection against SHIV-RT infection for up to 24 h, and underscores the need for future clinical testing of their safety and ability to prevent HIV transmission in humans.